Forus Raises $150M at a $3B Valuation as Its AI Network Becomes How Medicine Reaches Patients
Forus, the AI network accelerating medicine, today announced $150 million in Series C financing at a $3 billion valuation, tripling its valuation just months after announcing its Series B and bringing total funding to more than $300 million. The round was led by Bain Capital Ventures, an investor in Forus since its seed round. Every existing institutional investor is reinvesting, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel.
Forus and American Gastroenterological Association Announce Strategic Partnership to Improve Medication Access for GI Patients
Forus, the leader in AI-powered medication access and prior authorization, and the American Gastroenterological Association (AGA), the nonprofit medical society dedicated to advancing the science and practice of gastroenterology, today announced a strategic partnership to improve how the more than 60 million Americans living with digestive diseases get the therapies their clinicians prescribe.
Forus Raises $160M to Build the Foundation for Modern Medicine
Forus, the company accelerating medicine for the people who need it, prescribe it, and create it, today announced it has raised over $160M. Formerly known as Tandem, the company is backed by Thrive Capital, General Catalyst, Accel, Bain Capital Ventures (BCV), Redpoint, BoxGroup, and Pear VC.
